Literature DB >> 32296500

Effect of Roux-en-Y gastric bypass on the bioavailability of metoprolol from immediate and controlled release tablets: a single oral dose study before and after surgery.

Jan Peter Yska1, Jacquelien T M Wanders1, Blessing Odigie1, Jan A Apers2, Marloes Emous2, Erik R E Totté2, E Christiaan Boerma3, Froukje L Ubels4, Herman J Woerdenbag5, Henderik W Frijlink5, Bob Wilffert6,7, Eric N van Roon1,6.   

Abstract

Objective: Roux-en-Y gastric bypass (RYGB) surgery induces major changes in the gastrointestinal tract that may alter the pharmacokinetics of orally administered drugs. Results from pharmacokinetic studies are sparse. This study aimed to investigate the effect of RYGB on the bioavailability of metoprolol from immediate release (IR) and controlled release (CR) tablets in female patient volunteers before and after surgery.
Methods: An explorative, two-phase, single oral dose pharmacokinetic study of metoprolol in female patients undergoing RYGB was carried out. The dose was administered twice in each patient, 1 month before and 6 months after surgery. After intake of either 100 mg of metoprolol IR or CR tablet serum concentration-time profiles of metoprolol were determined. The endpoint was the ratio of AUCafter/AUCbefore of metoprolol.
Results: Twelve patients were included in the study (metoprolol IR: 7; metoprolol CR: 5). After intake of a metoprolol IR tablet major intraindividual and interindividual differences for area under the serum concentration versus time curve (AUC) of metoprolol before and after surgery were observed (range ratio AUC0-10 hours after/AUC0-10 hours before: 0.74-1.98). For metoprolol CR tablets a significant reduction in bioavailability of metoprolol was observed after surgery (range ratio AUC0-24 hours after/AUC0-24 hours before: 0.43-0.77).
Conclusion: RYGB may influence the bioavailability of metoprolol from an IR tablet. The magnitude of changes in bioavailability after RYGB requires close monitoring of patients using metoprolol IR tablets and dose adjustment if deemed necessary. RYGB clearly reduces the bioavailability of metoprolol from a CR tablet. After RYGB clinicians may consider to increase the dose according to clinical response. © European Association of Hospital Pharmacists 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  bioavailability; controlled release; gastric bypass surgery; immediate release; metoprolol; pharmacokinetics

Mesh:

Substances:

Year:  2019        PMID: 32296500      PMCID: PMC7147559          DOI: 10.1136/ejhpharm-2018-001804

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN: 2047-9956


  31 in total

Review 1.  A systematic review of drug absorption following bariatric surgery and its theoretical implications.

Authors:  R Padwal; D Brocks; A M Sharma
Journal:  Obes Rev       Date:  2009-06-02       Impact factor: 9.213

Review 2.  Altered drug disposition following bariatric surgery: a research challenge.

Authors:  H Karl Greenblatt; David J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2015-06       Impact factor: 6.447

3.  Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers.

Authors:  A B Luzier; A Killian; J H Wilton; M F Wilson; A Forrest; D J Kazierad
Journal:  Clin Pharmacol Ther       Date:  1999-12       Impact factor: 6.875

4.  Obesity and beta-blockers: influence of body fat on their kinetics and cardiovascular effects.

Authors:  F Galletti; M L Fasano; L A Ferrara; A Groppi; M Montagna; M Mancini
Journal:  J Clin Pharmacol       Date:  1989-03       Impact factor: 3.126

5.  Dumping syndrome following gastric bypass: validation of the dumping symptom rating scale.

Authors:  Anna Laurenius; Torsten Olbers; Ingmar Näslund; Jan Karlsson
Journal:  Obes Surg       Date:  2013-06       Impact factor: 4.129

Review 6.  Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease.

Authors:  G L Plosker; S P Clissold
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

7.  Investigation of drug absorption from the gastrointestinal tract of man. III. Metoprolol in the colon.

Authors:  J Godbillon; D Evard; N Vidon; M Duval; J P Schoeller; J J Bernier; J Hirtz
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

8.  Influence of bariatric surgery on the use of medication.

Authors:  Jan Peter Yska; Douwe H van der Meer; Albert R Dreijer; Willeke Eilander; Jan A Apers; Marloes Emous; Erik R E Totté; Bob Wilffert; Eric N van Roon
Journal:  Eur J Clin Pharmacol       Date:  2015-11-03       Impact factor: 2.953

9.  Dietary-Induced Obesity and Changes in the Biodistribution and Metabolism of Amiodarone in the Rat.

Authors:  Ali Abdussalam; Marwa Al-Agili; Hamdah M Al Nebaihi; Patrick R Mayo; Raniah Q Gabr; Dion R Brocks
Journal:  J Pharm Sci       Date:  2018-07-12       Impact factor: 3.534

10.  The effect of bariatric surgery on intestinal absorption and transit time.

Authors:  Kirstin A Carswell; Royce P Vincent; Ajay P Belgaumkar; Roy A Sherwood; Stephanie A Amiel; Ameet G Patel; Carel W le Roux
Journal:  Obes Surg       Date:  2014-05       Impact factor: 4.129

View more
  1 in total

Review 1.  Oral drug dosing following bariatric surgery: General concepts and specific dosing advice.

Authors:  Jurjen S Kingma; Desirée M T Burgers; Valerie M Monpellier; Marinus J Wiezer; Heleen J Blussé van Oud-Alblas; Janelle D Vaughns; Catherine M T Sherwin; Catherijne A J Knibbe
Journal:  Br J Clin Pharmacol       Date:  2021-06-03       Impact factor: 3.716

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.